STAT+: Hengrui, BeOne top new analysis of Chinese drug development
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
A new report is peeling back the curtain on Chinese pharmaceutical innovation, assessing which companies are best at driving the drug development that\u2019s captured the attention of pharmaceutical executives and investors worldwide.\u00a0<\/p>\n
On Sunday, IDEA Pharma and parent company SAI MedPartners released their inaugural China Pharmaceutical Innovation and Invention Index. The report joins a global pharmaceutical ranking<\/a> that IDEA produces every spring.\u00a0<\/p>\n The rankings were chosen from a list of 50 companies around China. The report ranks the top companies for invention \u2014 namely, which companies are developing new medicines that matter and use novel science \u2014 and innovation, which assesses how these companies are developing and launching medicines. Research spending, international patent filings, and drug approvals all factor into a company\u2019s standing.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n